These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 24860863

  • 1. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J.
    JAMA; 2014 Jul 02; 312(1):23-4. PubMed ID: 24860863
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Why using Avastin for eye disease is so difficult.
    Torjesen I.
    BMJ; 2012 May 01; 344():e3012. PubMed ID: 22549057
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Age-related visual loss].
    Neubauer AS, Kernt M.
    MMW Fortschr Med; 2013 Feb 07; 155(2):36-7. PubMed ID: 23573743
    [No Abstract] [Full Text] [Related]

  • 7. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R, Attanasio F, Palazzi N, Colombini S, Falai T, Cecchi M, Virgili G.
    Int J Clin Pharm; 2013 Aug 07; 35(4):507-9. PubMed ID: 23625322
    [No Abstract] [Full Text] [Related]

  • 8. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH, Toussaint BW, Miller DM, Petersen MR, Foster RE, Riemann CD, Hutchins RK, Sisk RA.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan 07; 46(1):62-6. PubMed ID: 25559511
    [Abstract] [Full Text] [Related]

  • 9. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G, Marata AM, Magrini N, Bero L.
    Cochrane Database Syst Rev; 2014 Sep 15; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Age-related macular degeneration].
    Kernt M, Wolf A, Kampik A.
    MMW Fortschr Med; 2013 Feb 07; 155(2):43-5; quiz 46-7. PubMed ID: 23573745
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.
    Br J Ophthalmol; 2015 Feb 07; 99(2):141-6. PubMed ID: 25271911
    [Abstract] [Full Text] [Related]

  • 19. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC, Barkmeier AJ, Hodge DO, Mahr MA.
    Ophthalmology; 2016 Jun 07; 123(6):1257-62. PubMed ID: 26976701
    [Abstract] [Full Text] [Related]

  • 20. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N.
    BMJ; 2012 May 09; 344():e3275. PubMed ID: 22573655
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.